Business Context and Reporting Period
This Form 8-K is filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata request) on May 3, 2018. The report serves to announce the company's financial results for the quarter ended March 31, 2018. The registrant is an emerging growth company that has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It references the Q1 2018 results press release for such data.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in the text of this 8-K. The document states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liability of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the correct registrant name is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Review Exhibit 99.1 (Press Release dated May 3, 2018) for actual Q1 2018 financial figures and operational updates.
- Note that the financial data in this filing is not deemed "filed" under Section 18 of the Exchange Act.
- Confirm the company's status as an emerging growth company and its election regarding accounting standard transition periods.